<PAGE> 1
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 10, 2001
DUSA PHARMACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
NEW JERSEY 0-19777 22-3103129
(State or other (IRS Employer
jurisdiction of (Commission Identification
incorporation) File Number) Number)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES, INCLUDING ZIP CODE)
(978) 657-7500
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
<PAGE> 2
ITEM 5. OTHER EVENTS.
The Registrant, DUSA Pharmaceuticals, Inc. ("DUSA") reports that it has
updated investors today at the JP Morgan H&Q Healthcare Conference in San
Francisco. Dr. Geoffrey Shulman, DUSA's President and CEO, and Dr. Stuart
Marcus, DUSA's VP, Scientific Affairs and CSO, discussed progress in the ongoing
US launch of LEVULAN(R) Photodynamic Therapy (PDT) for the treatment of
non-hyperkeratotic actinic keratoses (AKs); DUSA's aggressive expansion of its
LEVULAN PDT/PD (photodetection) development program; and DUSA's strong financial
position.
Except for historical information, this report and exhibit contain
certain forward-looking statements that involve known and unknown risks and
uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements relate to the expansion of
DUSA's development program and plans to initiate clinical trials for the
treatment of onychomychosis, warts, Barrett's esophagus and brain cancer;
intention to support and collaborate in investigator studies and consideration
of development of various additional detection and treatment programs. Such
risks and uncertainties include, but are not limited to, scientific, clinical
trial, and regulatory risks associated with drug and device development
programs, competitive products which may develop, DUSA's ability to fund these
programs through the complete regulatory process, intellectual property risks,
reimbursement by third-party payors, and other risks identified in DUSA's SEC
filings from time to time.
ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.
(c) Exhibits.
[99] Press Release dated January 10, 2001.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: JANUARY 10, 2001 By: /S/ D. GEOFFREY SHULMAN
---------------- --------------------------------------
D. Geoffrey Shulman, MD, FRCPC
President, Chief Executive Officer
